Last reviewed · How we verify
Sildenafil and Boceprevir — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Sildenafil and Boceprevir (Sildenafil and Boceprevir) — Imperial College London.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sildenafil and Boceprevir TARGET | Sildenafil and Boceprevir | Imperial College London | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sildenafil and Boceprevir CI watch — RSS
- Sildenafil and Boceprevir CI watch — Atom
- Sildenafil and Boceprevir CI watch — JSON
- Sildenafil and Boceprevir alone — RSS
Cite this brief
Drug Landscape (2026). Sildenafil and Boceprevir — Competitive Intelligence Brief. https://druglandscape.com/ci/sildenafil-and-boceprevir. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab